Compare Aurobindo Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GSK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GSK PHARMA AUROBINDO PHARMA/
GSK PHARMA
 
P/E (TTM) x 11.5 243.1 4.7% View Chart
P/BV x 2.1 10.8 19.6% View Chart
Dividend Yield % 0.5 1.5 33.9%  

Financials

 AUROBINDO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
GSK PHARMA
Mar-19
AUROBINDO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8303,595 23.1%   
Low Rs5271,253 42.1%   
Sales per share (Unadj.) Rs333.9184.7 180.8%  
Earnings per share (Unadj.) Rs40.426.3 153.5%  
Cash flow per share (Unadj.) Rs51.829.2 177.5%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.40.8 44.7%  
Book value per share (Unadj.) Rs237.1126.3 187.7%  
Shares outstanding (eoy) m585.91169.40 345.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.013.1 15.5%   
Avg P/E ratio x16.892.2 18.2%  
P/CF ratio (eoy) x13.183.1 15.8%  
Price / Book Value ratio x2.919.2 14.9%  
Dividend payout %6.276.1 8.1%   
Avg Mkt Cap Rs m397,569410,626 96.8%   
No. of employees `00017.95.0 360.0%   
Total wages/salary Rs m25,8495,372 481.2%   
Avg. sales/employee Rs Th10,956.96,306.7 173.7%   
Avg. wages/employee Rs Th1,447.71,083.1 133.7%   
Avg. net profit/employee Rs Th1,324.3898.0 147.5%   
INCOME DATA
Net Sales Rs m195,63631,281 625.4%  
Other income Rs m1,5531,023 151.8%   
Total revenues Rs m197,18932,304 610.4%   
Gross profit Rs m39,5196,009 657.7%  
Depreciation Rs m6,680486 1,374.4%   
Interest Rs m2,6266 43,766.7%   
Profit before tax Rs m31,7676,540 485.7%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881287 -306.8%   
Tax Rs m7,2692,373 306.3%   
Profit after tax Rs m23,6454,454 530.9%  
Gross profit margin %20.219.2 105.2%  
Effective tax rate %22.936.3 63.1%   
Net profit margin %12.114.2 84.9%  
BALANCE SHEET DATA
Current assets Rs m153,64520,061 765.9%   
Current liabilities Rs m120,42914,543 828.1%   
Net working cap to sales %17.017.6 96.2%  
Current ratio x1.31.4 92.5%  
Inventory Days Days13557 238.1%  
Debtors Days Days6414 453.0%  
Net fixed assets Rs m103,90914,343 724.5%   
Share capital Rs m5861,694 34.6%   
"Free" reserves Rs m138,32219,704 702.0%   
Net worth Rs m138,90821,398 649.2%   
Long term debt Rs m1,8002 89,975.0%   
Total assets Rs m264,54439,113 676.4%  
Interest coverage x13.11,091.0 1.2%   
Debt to equity ratio x00 13,860.4%  
Sales to assets ratio x0.70.8 92.5%   
Return on assets %9.911.4 87.1%  
Return on equity %17.020.8 81.8%  
Return on capital %23.831.9 74.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316534 18,224.0%   
Fx outflow Rs m40,5897,091 572.4%   
Net fx Rs m56,727-6,557 -865.1%   
CASH FLOW
From Operations Rs m16,2203,994 406.1%  
From Investments Rs m-28,768-1,433 2,007.0%  
From Financial Activity Rs m19,191-3,584 -535.5%  
Net Cashflow Rs m6,656-1,023 -650.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.0 10.2 77.9%  
FIIs % 27.7 23.8 116.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 102,036 68.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  FULFORD INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Lower; Energy and Healthcare Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 25, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS